ABIVAX Société Anonyme (EPA:ABVX)
94.10
-10.10 (-9.69%)
At close: Dec 16, 2025
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 2.04M EUR in the quarter ending September 30, 2025, with 2.00% growth. This brings the company's revenue in the last twelve months to 6.78M, down -31.84% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
6.78M
Revenue Growth
-31.84%
P/S Ratio
1,160.96
Revenue / Employee
98.30K
Employees
69
Market Cap
7.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | 14.00K | 21.00K | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
ABIVAX Société Anonyme News
- 8 hours ago - Europe's best-performing stock is up 1,400% this year. Here's what next - CNBC
- 9 hours ago - Citizens Raises Abivax (ABVX) Price Target to $131, Maintains Rating | ABVX Stock News - GuruFocus
- 9 hours ago - Abivax CEO: Looking for new partners in markets outside the U.S. - CNBC
- 11 hours ago - Abivax (ABVX) Reports Q3 EPS Loss but Maintains Strong Cash Position - GuruFocus
- 12 hours ago - Abivax GAAP EPS of -€2.10 - Seeking Alpha
- 14 hours ago - Abivax 9-month Net Loss Widens On Higher R&D Costs, Lower Operating Income - Nasdaq
- 4 days ago - Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q3 2025 Result - GuruFocus
- 4 days ago - Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 - Seeking Alpha